Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome.

Jacoby MA, Walter M.

Oncology (Williston Park). 2018 Dec 17;32(12):627-9. No abstract available.

2.

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Jacoby MA, Trinkaus K, Walter MJ.

N Engl J Med. 2018 Dec 13;379(24):2380. doi: 10.1056/NEJMc1813470. No abstract available.

PMID:
30575467
3.

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Wang T, Jacoby MA, Duncavage EJ, Miller CA, Heath S, Rahme R, Fenaux P, Ades L, Renneville A, Cassinat B, Takeshita A, Asou N, Miyazaki Y, Kiyoi H, Ravandi F, Westervelt P, Wartman LD, Welch JS.

Br J Haematol. 2019 Jun;185(5):984-987. doi: 10.1111/bjh.15681. Epub 2018 Nov 22. No abstract available.

PMID:
30467844
4.

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, Wartman LD, Christopher MJ, Pusic I, Welch JS, Uy GL, Link DC, DiPersio JF, Westervelt P, Ley TJ, Trinkaus K, Graubert TA, Walter MJ.

N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.

5.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Robinson J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Pusic I, Welch JS, Link DC, DiPersio JF, Westervelt P, Ley TJ, Graubert TA, Walter MJ.

JCI Insight. 2018 Mar 8;3(5). pii: 98962. doi: 10.1172/jci.insight.98962.

6.

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS.

Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

7.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.

Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF.

Blood Cancer J. 2017 Mar 10;7(3):e542. doi: 10.1038/bcj.2017.21. No abstract available.

8.

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ, Welch JS.

Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12. No abstract available.

9.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

10.

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.

Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reineck T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, DiPersio JF, Wilson RK, Link DC, Welch JS, Ley TJ, Graubert TA, Westervelt P, Walter MJ.

Leukemia. 2017 Apr;31(4):872-881. doi: 10.1038/leu.2016.282. Epub 2016 Oct 14.

11.

Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome.

Duncavage EJ, O'Brien J, Vij K, Miller CA, Chang GS, Shao J, Jacoby MA, Heath S, Janke MR, Elliott K, Fulton RS, Fronick C, O'Laughlin M, Westervelt P, Ley TJ, Wilson RK, Walter MJ.

Leukemia. 2016 Dec;30(12):2422-2426. doi: 10.1038/leu.2016.247. Epub 2016 Aug 30. No abstract available.

12.

A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.

Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R.

Leuk Lymphoma. 2016 Nov;57(11):2535-40. doi: 10.3109/10428194.2016.1173213. Epub 2016 Apr 27.

PMID:
27122296
13.

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R.

Leuk Lymphoma. 2016;57(3):728-30. doi: 10.3109/10428194.2015.1076930. Epub 2015 Oct 5. No abstract available.

14.

Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing.

Jacoby MA, Duncavage EJ, Walter MJ.

Trends Cancer. 2015 Dec;1(4):231-241. doi: 10.1016/j.trecan.2015.10.006. Epub 2015 Nov 25. Review.

PMID:
28741514
15.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. doi: 10.1016/j.bbmt.2015.05.026. Epub 2015 Jun 5.

16.

Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Jacoby MA, Martin MG, Uy GL, Westervelt P, Dipersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN.

Am J Hematol. 2014 May;89(5):487-92. doi: 10.1002/ajh.23663. Epub 2014 Mar 3.

17.

The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.

Jacoby MA, De Jesus Pizarro RE, Shao J, Koboldt DC, Fulton RS, Zhou G, Wilson RK, Walter MJ.

Leukemia. 2014 Jun;28(6):1242-51. doi: 10.1038/leu.2013.368. Epub 2013 Dec 5.

18.

Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon.

Ramsingh G, Jacoby MA, Shao J, De Jesus Pizzaro RE, Shen D, Trissal M, Getz AH, Ley TJ, Walter MJ, Link DC.

Blood. 2013 Oct 10;122(15):e44-51. doi: 10.1182/blood-2013-03-488007. Epub 2013 Sep 5.

19.

Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.

Jacoby MA, Walter MJ.

Expert Rev Mol Diagn. 2012 Apr;12(3):253-64. doi: 10.1586/erm.12.18. Review.

PMID:
22468816
20.

Systematic mutagenesis of the murine gammaherpesvirus 68 M2 protein identifies domains important for chronic infection.

Herskowitz JH, Siegel AM, Jacoby MA, Speck SH.

J Virol. 2008 Apr;82(7):3295-310. doi: 10.1128/JVI.02234-07. Epub 2008 Jan 30.

21.

Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice.

Tarakanova VL, Suarez F, Tibbetts SA, Jacoby MA, Weck KE, Hess JL, Speck SH, Virgin HW 4th.

J Virol. 2005 Dec;79(23):14668-79.

22.

The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells.

Herskowitz JH, Jacoby MA, Speck SH.

J Virol. 2005 Feb;79(4):2261-73. Erratum in: J Virol. 2011 Mar;85(6):3041. Herskowitz, Jeremy [corrected to Herskowitz, Jeremy H].

23.

Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection.

Tibbetts SA, Loh J, Van Berkel V, McClellan JS, Jacoby MA, Kapadia SB, Speck SH, Virgin HW 4th.

J Virol. 2003 Jul;77(13):7696-701.

25.

Effectiveness of protein A for antibody immobilization for a fiber optic biosensor.

Anderson GP, Jacoby MA, Ligler FS, King KD.

Biosens Bioelectron. 1997;12(4):329-36.

PMID:
9178518

Supplemental Content

Loading ...
Support Center